In December 2024, Atheron Therapeutics was established with a clear mission: to build a next-generation biopharmaceutical company driven by innovation, scientific rigor, and a deep commitment to transforming patient outcomes. From day one, the company set out to bridge cutting-edge science with meaningful clinical impact.
In March 2025, Atheron filed its first patent, a critical step that formally establishes its intellectual property foundation. This filing not only protects the company’s proprietary technology but also signals the maturation of its discovery platform toward clinical-ready assets.
In June 2025, Atheron Laboratory was officially established, bringing together state-of-the-art capabilities in antibody discovery, protein engineering, and high-throughput screening. This dedicated facility empowers the company to execute on its vision of developing next-generation therapeutics, with integrated workflows designed to rapidly advance candidates from concept to validation.
In November 2025, the biology discovery platform officially launched its first antibody screening campaign, marking a significant milestone. This critical step will leverage advanced screening technologies to accelerate the development of next-generation therapeutics.
Atheron Therapeutics announced that new and updated data from multiple studies of its proprietary compounds were presented at the AACR Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
